Vebicorvir
CAS No. 2090064-66-5
Vebicorvir( ABI-H0731 )
Catalog No. M23939 CAS No. 2090064-66-5
Vebicorvir is a first-generation hepatitis B virus (HBV) core protein inhibitor, has demonstrated effective antiviral activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 126 | In Stock |
|
| 5MG | 122 | In Stock |
|
| 10MG | 202 | In Stock |
|
| 25MG | 337 | In Stock |
|
| 50MG | 461 | In Stock |
|
| 100MG | 644 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVebicorvir
-
NoteResearch use only, not for human use.
-
Brief DescriptionVebicorvir is a first-generation hepatitis B virus (HBV) core protein inhibitor, has demonstrated effective antiviral activity.
-
DescriptionVebicorvir is a first-generation hepatitis B virus (HBV) core protein inhibitor, has demonstrated effective antiviral activity.
-
In VitroVebicorvir (ABI-H0731) demonstrates inhibition of pgRNA, HBeAg, and HBsAg production, with EC50s of 2.68?μM, 4.95?μM, and 7.30?μM, respectively.Vebicorvir (ABI-H0731) is an inhibitor of pgRNA encapsidation and rcDNA synthesis.
-
In VivoAfter i.v. administration, the drug rapidly distributes and decayes in a biphasic manner in all species tested. Plasma clearance values of ABI-H0731 were 8.05, 10.1, 14.7, and 4.86?ml/min/kg, representing 9, 16, 47, and 11% of liver blood flow, in mouse, rat, dog, and monkey, respectively.
-
SynonymsABI-H0731
-
PathwayMicrobiology/Virology
-
TargetHBV
-
RecptorHBV DNA
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2090064-66-5
-
Formula Weight467.44
-
Molecular FormulaC19H12F3N3O4S2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (213.93 mM)
-
SMILESO=C(c(cc1)cc(NC(c2c3cccc2)=O)c1S3(=O)=O)NCc1cnc(C(F)(F)F)s1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Huang Q, Cai D, Yan R, Li L, Zong Y, Guo L, Mercier A, Zhou Y, Tang A, Henne K, Colonno R. Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01463-20.
molnova catalog
related products
-
Canocapavir
Canocapavir (ZM-H1505R) is a novel orally available HBV coat protein modulator with antiviral activity that induces conformational changes in the linker region of the HBV core protein, and can be used for the treatment of hepatitis B virus.
-
HAP-12
HAP-12 is a small molecule HBV capsid assembly effector that inhibits HBV DNA replication with EC50 of 0.5 uM.
-
Helioxanthin derivat...
Helioxanthin derivative 5-4-2 (Helioxanthin 5-4-2) is an analogue of helioxanthin that shows anti-HBV activity in vitro and can be used to study HBV.
Cart
sales@molnova.com